Delaware Healthcare R
(DLRHX)
US Markets Closed
AdChoices
20.20
+0.38
+1.92%
:

Previous Close

19.82

Net Assets

4.34M

Yield

0.00%

Front load

None

Expenses

1.63%

Category

Health

Morningstar Risk

Above Average

Morningstar Rating ★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • DLRHX

  • Category

    • 2013

    • 50.28%

    • -

    • 2012

    • 18.61%

    • -

    • 2011

    • 2.58%

    • -

    • 2010

    • 15.50%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 17.44%

      • 18.35%

      • 9.08%

      • Q2

      • 8.65%

      • -5.58%

      • 4.42%

      • Q3

      • 9.76%

      • 3.13%

      • -16.03%

      • Q4

      • 7.31%

      • 2.93%

      • 7.25%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Eli Lilly and Co

        • 8.48

        • 600,000

        • 28,000

        • GlaxoSmithKline PLC ADR

        • 5.87

        • 538,000

        • 0

        • Teva Pharmaceutical Industries Ltd ADR

        • 5.84

        • 500,000

        • 57,000

        • UCB SA

        • 5.38

        • 249,785

        • 0

        • Pfizer Inc

        • 5.23

        • 800,000

        • 390,000

        • WellPoint Inc

        • 3.89

        • 150,000

        • -50,000

        • Bristol-Myers Squibb Company

        • 3.85

        • 341,737

        • 0

        • Fresenius Medical Care AG & Co. KGaA

        • 3.61

        • 230,000

        • 0

        • Chugai Pharmaceutical Co Ltd

        • 3.44

        • 488,300

        • 0

        • Boston Scientific Inc

        • 3.10

        • 1,100,000

        • 50,000

        • Name

        • Rating

        • YTD Return %

          • VALIC Company I Health Sciences

          • ★★★★★
          • 19.62

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 18.54

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 19.88

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 18.82

          • Janus Global Life Sciences D

          • ★★★★
          • 20.52

          • Janus Global Life Sciences I

          • ★★★★
          • 20.60

          • Janus Global Life Sciences S

          • ★★★★
          • 20.19

          • Franklin Biotechnology Discovery A LW

          • ★★★★
          • 20.72

          • BlackRock Health Sciences Opps Inv C

          • ★★★★
          • 17.47

          • Fidelity Advisor® Biotechnology A

          • ★★★★
          • 19.77

          • Name

          • DLRHX

          • Category

            • Expense Ratio

            • 1.63%

            • 1.45%

            • Net Assets

            • 4.34M

            • 711.24M

            • Dividend Yield

            • 1.70%

            • 0.61

            • Price/Book

            • 3.03

            • 4.82

            • Price/Sales

            • 1.88

            • 3.25

            • Price/Cash Flow

            • 10.25

            • 19.29

            Profile

            Name of Issuer

            Delaware Investments

            Fund Style

            Open

            Fund Manager

            Liu-Er Chen

            Investment Style

            Large Growth

            The investment seeks maximum long-term capital growth through capital appreciation. The fund invests at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry. It invests in U.S. and non-U.S. companies across all market capitalizations. The fund may invest up to 50% of its total assets in non-U.S. companies. It is non-diversified.

            Purchase Information

            Initial Purchase 0
            Initial Purchase: IRA NA
            Initial Purchase: AIP NA
            Front load None
            Back Load None

            Inception

            1/28/2010